Incretins and the intensivist: what are they and what does an intensivist need to know about them?
Mark P Plummer, Marianne J Chapman, Michael Horowitz, Adam M Deane
Critical Care | BIOMED CENTRAL LTD | Published : 2014
Hyperglycaemia occurs frequently in the critically ill, even in those patients without a history of diabetes. The mechanisms underlying hyperglycaemia in this group are complex and incompletely defined. In health, the gastrointestinal tract is an important modulator of postprandial glycaemic excursions and both the rate of gastric emptying and the so-called incretin hormones, glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide, are pivotal determinants of postprandial glycaemia. Incretin-based therapies (that is, glucagon-like peptide- 1 agonists and dipeptidyl-peptidase-4 inhibitors) have recently been incorporated into standard algorithms for the management of hypergly..View full abstract
Awarded by NHMRC
MPP is financially supported by a Dawes Scholarship, co-funded by the University of Adelaide and the Royal Adelaide Hospital. This work was supported by NHMRC Project Grant No. 1025648.